SASKATOON, Aug. 6, 2015 /CNW/ - Prairie Plant Systems Inc. and CanniMed Ltd. have successfully received Section 56 exemptions under the Marihuana for Medical Purposes Regulations (MMPR) governed by Health Canada and as a result have begun oil
manufacturing for patients.
Similar to the seven dry cannabis products currently being offered,
CanniMed® oils will be available in three distinct THC-to-CBD ratios:
CanniMed® oil 18:0 - containing 18.3 mg/ml THC and 0.2 mg/ml CBD
CanniMed® oil 10:10 - containing 9.7 mg/ml THC and 10.3 mg/ml CBD
CanniMed® oil 1:20 - containing 1.2 mg/ml THC and 20.5 mg/ml CBD
"We are very proud to be among the first licensed producers to receive
the go ahead from Health Canada to manufacture CanniMed oils for our
patients," said Brent Zettl, President and CEO of Prairie Plant Systems
Inc. and CanniMed Ltd. "Patient requests for oils have been significant
with as many as 67 per cent responding to an informal survey suggesting
they would prefer this delivery method over smoking or vaporizing."
CanniMed® oil will be packaged in 60 ml bottles and include an oral
syringe for consistent dosing and as a spill prevention.
About CanniMed and Prairie Plant Systems
CanniMed Ltd. was the first producer to be licensed under the Marihuana for Medical Purposes Regulations (MMPR). Our pharmaceutical-grade cannabis is produced under Good
Manufacturing Practices (GMP) regulations, the criteria used to
manufacture all pharmaceuticals in Canada. Our primary focus is on
patient safety, undertaken by strictly following a 281 point quality
CanniMed's parent company, Prairie Plant Systems Inc. was the sole
supplier to Health Canada under the former medical marijuana system for
13 years, and has been producing safe and consistent medical marijuana
for thousands of Canadian patients, with no incident of diversion.
These two companies together have created the leading medical cannabis
company in Canada with a strong corporate priority to design and
execute clinical research that will close the gap between the anecdotal
benefit and evidence based medicine in order to standardize care. Our
Canadian-grown cannabis is already leading the way in standardizing
care and has been used in a published clinical trial demonstrating the
efficacy of smoked cannabis for chronic pain,1 which was used in the development of the Canadian Pain Society's Pharmacological management of chronic neuropathic pain: Revised
consensus statement positioning medical cannabis as third line treatment for neuropathic
1 Ware, M.A., Wang, T., Shapiro, S., Robinson, A. and others. (2010) Smoked Cannabis for Chronic Pain: a Randomized Controlled Trial. Canadian Medical Association Journal (CMAJ). 182:E694-E701.
2 Moulin, D.E., Boulanger, A., Clark A.J., Dao, T. and others. (2014)
Pharmacological Management of Chronic Neuropathic Pain: Revised
Consensus Statement from the Canadian Pain Society. Pain Research and Management. Nov-Dec; 19(6): 328-335.
SOURCE CanniMed Ltd.
Image with caption: "CanniMed Ltd. logo. (CNW Group/CanniMed Ltd.)". Image available at: http://photos.newswire.ca/images/download/20150806_C9408_PHOTO_EN_44115.jpg
For further information:
Dara Willis Communications